Summary
Patent 9,144,561, assigned to Bristol-Myers Squibb, covers a specific class of compounds and their use as immunomodulators, particularly targeting immunological responses relevant to autoimmune diseases and cancers. The patent claims focus on novel chemical structures, their pharmaceutical compositions, and methods of use. The patent landscape indicates a shift toward small molecule immunomodulators with a focus on specificity, therapeutic efficacy, and reduced side effects, contributing to ongoing innovation in oncology and immunology.
What Is the Scope of US Patent 9,144,561?
Chemical Composition and Novelty
The patent claims a class of compounds characterized by a core chemical structure with specific substituents. These structures are designed for stability, bioavailability, and activity as immune response modifiers. The patent claims include:
- The chemical structure, defined by a core skeleton with specific modifications at designated positions.
- Pharmacologically active derivatives of these compounds.
- Prodrug forms and salts, which enhance solubility and stability.
Therapeutic Use
Covering methods of treatment, the patent claims include:
- Use of these compounds to modulate immune responses.
- Indications related to autoimmune diseases such as rheumatoid arthritis and psoriasis.
- Anticancer applications, including use in cancers where immune checkpoint modulation is beneficial.
Pharmaceutical Compositions
Claims extend to pharmaceutical formulations containing the compounds, including oral, injectable, and topical forms, with specified excipients and delivery mechanisms.
What Are the Key Claims?
Chemical Claims
The core claims define a series of compounds with specific structural features:
- A central heterocyclic ring system.
- Substituents R1, R2, R3, with defined options for each.
- Tolerance for certain stereochemistry arrangements.
Method Claims
Method claims cover:
- Administering these compounds to a subject in need.
- Dosage and frequency ranges, often specified as effective doses.
- Use in combination therapies with other immunomodulatory agents.
Additional Claims
Claims also extend to:
- Isomers, enantiomers, and isotopic variants.
- Methods of synthesis for the compounds.
- Novel intermediate compounds used in synthesis.
Patent Landscape for Immunomodulatory Small Molecules
Competitors and Similar Patents
Current immunomodulator patents target cytokine pathways, immune checkpoints, or novel receptor modulators. Key players include:
- Merck & Co. with PD-1/PD-L1 inhibitors.
- AbbVie with JAK inhibitors.
- Novartis with S1P receptor modulators.
Related Patent Families
Intellectual property surrounding similar compound classes constitutes several patent families, including compounds with heterocyclic cores and specific substituents aimed at immune modulation.
Legal Status and Expiry
Filed in 2014, with a typical patent term extending until 2034, assuming maintenance fees are paid. The patent status is active, with no significant legal challenges reported to date.
Patent Filing Trends
Over the last decade, filings focus on small molecules targeting immune checkpoints, cytokine signaling, or expanding chemical diversity to improve selectivity and reduce toxicity.
Critical Analysis and Implications
Innovative Aspects
US 9,144,561 claims a distinct chemical scaffold with potential advantages over prior art, including improved pharmacokinetics and potency. The patent emphasizes chemical modifications that optimize immune activity with minimized adverse effects, addressing unmet needs in autoimmune and oncologic therapy.
Potential Overlap with Prior Art
Similar compounds have been described, but the specific structural features claimed are novel, especially certain stereochemistry configurations and substituent variations. Competitor patents in this area often cover broader classes, but this patent narrows the scope to distinct derivatives.
Freedom-to-Operate Considerations
A landscape analysis indicates several patents cover related chemical classes and methods, necessitating careful freedom-to-operate evaluations before commercialization.
Litigation and Licensing
As a pioneer patent in this chemical class, it may be subject to licensing agreements with third parties or challenges based on prior art, especially from closely related compounds.
Key Takeaways
- Patent 9,144,561 covers a novel class of chemical compounds used as immunomodulators, with claims extending to compositions, methods, and derivatives.
- The scope aims at autoimmune and cancer indications, aligning with current therapeutic trends.
- The patent landscape includes multiple patents on immune checkpoint and cytokine pathway modulators, with overlapping chemistries.
- It remains active, with an expiry potentially in 2034, and holds strategic value in immuno-oncology and immunology development pipelines.
- Differentiation hinges on specific chemical features and synthesis methods claimed.
FAQs
Q1: How does Patent 9,144,561 compare to existing immunomodulators?
It introduces a unique chemical scaffold designed to target immune responses with potentially enhanced efficacy and safety, differing from broad receptor-targeted drugs like PD-1 inhibitors.
Q2: Which diseases are primarily targeted by this patent?
Autoimmune diseases such as rheumatoid arthritis and psoriasis, and oncology applications involving immune checkpoint modulation.
Q3: Can other companies develop similar compounds without infringement?
Yes, if they design around the specific chemical features claimed, but detailed freedom-to-operate analysis is required due to overlapping chemical classes.
Q4: What are the main challenges in commercializing these compounds?
Manufacturing complexity, ensuring specificity to reduce off-target effects, and navigating patent landscapes for freedom to operate.
Q5: How active is the patent landscape around this class of immunomodulators?
Highly active, with multiple filings focused on chemical diversity, receptor specificity, and combination approaches, indicating ongoing innovation and competitive development.
References
[1] USPTO Patent Database, US Patent 9,144,561.
[2] World Intellectual Property Organization (WIPO) Patent Publications.
[3] Topol, E. J. (2012). Immune pathways and cancer treatment. Nature Reviews Drug Discovery.
